ANAB

46.6301.62%
DR

Daniel R. Faga

CEO, President & Director

Mr. Daniel R. Faga, MBA., also known as Dan, is President, Chief Executive Officer and Director of AnaptysBio, Inc. from August 2023. He was Interim President & CEO and Director of AnaptysBio, Inc. from March 21, 2022 to August 2023. He was Director of AnaptysBio, Inc. from November 2021 to March 21, 2022. He is Director of Seawolf Therapeutics, Inc. He serves as the Chief Executive Officer at First Tracks Biotherapeutics, Inc. and serves as its President and Director since March 2026. He is Advisor of 8VC. He is Director of Affini-T Therapeutics, Inc. from April 2022. He was Chief Business Officer of Spark Therapeutics, Inc. from May 04, 2016. He joined the Spark Therapeutics, Inc. on May 04, 2016. He was Chief Operating Officer of Mirati Therapeutics, Inc. until November 01, 2021. He was Executive VP, COO & Principal Financial Officer of Mirati Therapeutics, Inc. from 2021. He was Executive VP, COO & Principal Financial Officer of Mirati Therapeutics, Inc. from January 06, 2020 to 2021. He was Executive VP & COO of Mirati Therapeutics, Inc. He was employed at Mirati Therapeutics, Inc. until November 01, 2021. From July 2009 until April 2016, Mr. Faga was a Managing Director at Centerview Partners, an investment banking and advisory firm, where he served as a founding member of Centerview’s healthcare advisory practice. from May 2016 through December 2019, where he was responsible for leading the company’s corporate strategy, portfolio and new product planning, patient advocacy, business development, alliance management, asset & program management and corporate communications functions. Prior to Centerview, Mr. Faga worked at Merrill Lynch in its healthcare investment banking group and as a management consultant in the Life Sciences Practice at PRTM. He has B.S. in Engineering from Cornell University, M.B.A. in Healthcare Administration from University of Pennsylvania - The Wharton School.

Positions